Evidence map›Paper›PMID 30341536›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.

Joseph M Brandwein, Jack T Seki, Eshetu G Atenafu, Amr Rostom, Andrzej Lutynski, Anna Rydlewski, Aaron D Schimmer, Andre C Schuh, Vikas Gupta, Karen W L Yee

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Joseph M BrandweinDivision of Hematology, Department of Medicine, University of Alberta, 11350 - 83 Ave., Suite 4-112 CSB, Edmonton, AB, T6G 2G3, Canada. jbrandwe@ualberta.ca.ORCID http://orcid.org/0000-0001-9095-8789
Jack T SekiPharmacy Department, Princess Margaret Cancer Centre, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Eshetu G AtenafuBiostatistics Department, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Amr RostomDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Andrzej LutynskiDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Anna RydlewskiDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Aaron D SchimmerDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Andre C SchuhDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Vikas GuptaDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Karen W L YeeDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
University of Toronto · CAPrincess Margaret Cancer Centre · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the widespread use of 5-HT

Indexed as

AgedAntiemeticsAprepitantFemaleHumansInduction ChemotherapyLeukemia, Myeloid, AcuteMaleMiddle AgedProspective StudiesRetrospective StudiesAntiemeticsAprepitantAcute myeloid leukemiaAnti-emeticsChemotherapyNeurokinin inhibitors

Identifiers

PMID30341536
OpenAlexW2896095031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.